CN1321468A - Freeze-dried plasma without blood group and its preparation method - Google Patents
Freeze-dried plasma without blood group and its preparation method Download PDFInfo
- Publication number
- CN1321468A CN1321468A CN01106637A CN01106637A CN1321468A CN 1321468 A CN1321468 A CN 1321468A CN 01106637 A CN01106637 A CN 01106637A CN 01106637 A CN01106637 A CN 01106637A CN 1321468 A CN1321468 A CN 1321468A
- Authority
- CN
- China
- Prior art keywords
- blood plasma
- type
- blood
- plasma
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 43
- 239000008280 blood Substances 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 239000003223 protective agent Substances 0.000 claims abstract description 10
- 241000700605 Viruses Species 0.000 claims abstract description 8
- 210000002381 plasma Anatomy 0.000 claims description 97
- 238000000034 method Methods 0.000 claims description 8
- 230000002779 inactivation Effects 0.000 claims description 6
- 108090000190 Thrombin Proteins 0.000 claims description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 4
- 229960004072 thrombin Drugs 0.000 claims description 4
- 101710186708 Agglutinin Proteins 0.000 claims description 3
- 101710146024 Horcolin Proteins 0.000 claims description 3
- 101710189395 Lectin Proteins 0.000 claims description 3
- 101710179758 Mannose-specific lectin Proteins 0.000 claims description 3
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 claims description 3
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 claims description 3
- 239000000910 agglutinin Substances 0.000 claims description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 108010049003 Fibrinogen Proteins 0.000 claims description 2
- 102000008946 Fibrinogen Human genes 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 108010024636 Glutathione Proteins 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000001110 calcium chloride Substances 0.000 claims description 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 2
- 229940012952 fibrinogen Drugs 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 229960003180 glutathione Drugs 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 238000012856 packing Methods 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 239000002002 slurry Substances 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 238000000108 ultra-filtration Methods 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 239000002994 raw material Substances 0.000 abstract description 4
- 230000000415 inactivating effect Effects 0.000 abstract description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 abstract 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 abstract 1
- 239000003114 blood coagulation factor Substances 0.000 abstract 1
- 238000004108 freeze drying Methods 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
- 230000004520 agglutination Effects 0.000 description 5
- 230000009849 deactivation Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000007926 Craterellus fallax Nutrition 0.000 description 1
- 240000007175 Datura inoxia Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a freeze-dried plasma without blood type suitable for clinical various patients with different blood type and its preparation method. It is made up by mixing 5-10 portions of plasma type A, 2-7 portions of plasma type B, 0.5-3 portions of plasma type O and 0.5-3 portions of plasma type AB, virus inactivating, adding proper quantity of protective agent, and freeze-drying to obtain the invented product with extensive raw material source, convenient simple application, high recovery rate in various coagulation factors and universal, effective and safety.
Description
The present invention relates to that a kind of to be suitable for clinical various blood types patient defeated in order to freeze-dried plasma without blood group of replenishing its blood of human body and preparation method thereof, belong to a kind of blood plasma product.
Closely during the last ten years, along with blood transfusion physiological and pathological research deeply and the accumulation of clinical experience, blood plasma is increasing as a kind of supplement application clinically of blood of human body.Because A, B, O and four kinds of blood groups of AB of in the human body ABO blood group system, existing, at present, at the patient of four kinds of different blood groups, the defeated usefulness of blood plasma, the one, need the blood plasma of four kinds of different blood groups of preparation, the blood plasma product of preparation must separate storage; The 2nd, must carry out blood group determination to defeated with the person, this brings a lot of inconvenience not only for the use of blood plasma, and sometimes also can incur loss through delay the rescue to the emergency case.For solving the problem of above-mentioned existence, a kind of universally applicable blood plasma is disclosed in Chinese patent communique CN1272061A, this blood plasma can be regardless of the patient that blood group is common to various blood types, has brought very big convenience for the use of blood plasma.Yet the making of this universally applicable blood plasma mainly adopts A type and Type B blood plasma to mix, seldom adopt or without AB type blood plasma, O type blood plasma fully need not, these raw material sources that just make blood plasma make are subjected to very big restriction; Secondly, this blood plasma does not carry out the detection of anti-A, anti-B agglutination titer as yet, therefore, remains some gaps from the clinical use of reality; In addition, this blood plasma is the yield rate of not mentioned thrombin also, and thrombin is a key factor of the defeated usefulness person's coagulation function of influence.
The objective of the invention is the deficiency that exists at above-mentioned prior art and a kind of freeze-dried plasma without blood group is provided, it is not only easy to use, and raw material sources are extensive, possesses the practicality of clinical use fully, safety and effectiveness.
Another object of the present invention is the preparation method that a kind of freeze-dried plasma without blood group will be provided.
Purpose of the present invention is realized by following technical scheme: mix by following capacity ratio by A, B, O and four kinds of blood group blood plasma of AB type, behind inactivation of virus, add an amount of protective agent, and freeze through revolving, lyophilizing is prepared from:
A type blood plasma 5-10 part Type B blood plasma 2-7 part
O type blood plasma 0.5-3 part AB type blood plasma 0.5-3 part.
Press such scheme, four kinds of blended optimum ratios of blood group blood plasma of the present invention are:
A type blood plasma 5-7 part Type B blood plasma 3-6 part
O type blood plasma 0.5-2 part AB type blood plasma 0.5-2 part.
The dosage form of blood plasma of the present invention is the frozen dry blood plasma preparation, becomes the dry powder powder.
The agglutinin of blood plasma of the present invention is tired and is anti-A≤1: 4-1: 8, and anti-B≤1: 8-1: 16.
Virus inactivating method of the present invention is: adopting organic solvent/detergent is S/D deactivation method, concrete steps are: the TNBP with 1% adds 1% TntonX-100 and handled blood plasma 4 hours at 30 ℃, use vegetable oil (soybean oil) extraction organic solvent TNBP then, remove no ion detergent TritonX-100 with Prepcl8 solid phase chromatography method, make the residual quantity of S/D be lower than required standard.Adopt the effectively lipid-coated virus in the deactivation blood plasma of S/D deactivation method, behind the infusion human body untoward reaction few, do not have the danger of propagation hepatitis B, hepatitis C and acquired immune deficiency syndrome (AIDS).
Protective agent of the present invention is: calcium chloride, sucrose, mannitol, glucose and glutathione, wherein any one or multiple.
Preparation process of the present invention is: the qualified blood plasma speed that will gather is put-30 ℃ of stored frozen; proportioning is mixed four kinds of molten slurries of blood group blood plasma by measure; add an amount of protective agent, carry out viral inactivation treatment, ultrafiltration and concentration with the S/D method; add protective agent again; adjust pH value 7.4 ± 1.0, the degerming packing is revolved under≤-30 ℃ temperature at last and is frozen; lyophilizing is handled under≤35 ℃ temperature and in≤50 hour time again, becomes the frozen dry blood plasma preparation.
Good effect of the present invention and characteristic are: 1, the present invention adopts four kinds of blood group blood plasma to mix, and its raw material sources more horn of plenty are extensive; 2, pass through the mixing of four kinds of blood group blood plasma proper proportions, make the anti-A, the anti-B antibody (agglutinin) that exist in the blood plasma be neutralized, dilute, and in preparation process, reduce or removal, through detection to a plurality of embodiment of the present invention, its anti-A agglutination titer and anti-B agglutination titer are all below 1: 8, meet 1: 16 human body blood transfusion standard fully, can be by the defeated usefulness of the patient of clinical various blood types, easy to use simple and direct; 3, carry out S/D method inactivation of virus, not only method is easy, and effectively deactivation and eliminate HBV, HCV in the blood plasma and virus that menses such as HIV are propagated, has guaranteed the safety of clinical use; 4, raw blood plasma speed is put-30 ℃ of stored frozen in preparation process, and add an amount of protective agent, adopt low temperature to revolve simultaneously to freeze and processing mode such as the lyophilizing of prescribing a time limit, thereby, can stablize in the blood plasma various factor Xas avoid the influence of chemical factors, except that various protein ingredients were arranged, the response rate of main thrombin such as Fibrinogen, the V factor, the VIII factor, the IX factor, the X factor had guaranteed the effectiveness of blood plasma product all more than 65% in the assurance preparation; 5, it is long that frozen dry blood plasma of the present invention has the holding time, is convenient to transportation, is suitable for war preparedness, characteristics easy to use.
The preferred embodiments of the present invention are as shown in the table:
| Group | Various blood plasma mixed proportion (%) | The agglutination titer titre | Remarks | ||||
| The A type | Type B | The O type | The AB type | Anti-A | Anti-B | ||
| ????1# | ????50 | ????20 | ????20 | ????10 | ?1∶2 | ?1∶8 | |
| ????2# | ????50 | ????30 | ????10 | ????10 | ?1∶2 | ?1∶4 | |
| ????3# | ????60 | ????30 | ????5 | ????5 | ?1∶2 | ?1∶4 | |
| ????4# | ????50 | ????35 | ????5 | ????10 | ?1∶2 | ?1∶4 | |
By the agglutination titer of mixed blood plasma, must not greater than 1: 16 be standard, more than respectively organize the requirement that pooled plasma all meets no blood group blood plasma.
The blood plasma dosage form of the various embodiments described above is the frozen dry blood plasma preparation.
Claims (10)
1, a kind of freeze-dried plasma without blood group is characterized in that being mixed by following capacity ratio by A, B, O and four kinds of blood group blood plasma of AB type, and behind inactivation of virus, adds that an amount of protective agent freezes through revolving, lyophilizing is prepared from:
A type blood plasma 5-10 part Type B blood plasma 2-7 part
O type blood plasma 0.5-3 part AB type blood plasma 0.5-3 part.
2, by the described no blood group inactivation of virus blood plasma of claim 1, it is characterized in that four kinds of blended optimum ratios of blood group blood plasma are:
A type blood plasma 5-7 part Type B blood plasma 3-6 part
O type blood plasma 0.5-2 part AB type blood plasma 0.5-2 part.
3, by claim 1 or 2 described freeze-dried plasma without blood group, the agglutinin that it is characterized in that blood plasma is tired and is anti-A≤1: 4-1: 8, and anti-B≤1: 8-1: 16.
4, by claim 1 or 2 described freeze-dried plasma without blood group, it is characterized in that described protective agent is: calcium chloride, sucrose, mannitol, glucose and glutathione, wherein any one or multiple.
5,, it is characterized in that in the described blood plasma that except that various protein ingredients were arranged, the response rate of main thrombin such as Fibrinogen, the V factor, the VIII factor, the IX factor, the X factor was all more than 65% by claim 1 or 2 described freeze-dried plasma without blood group.
6, by claim 1 or 2 described freeze-dried plasma without blood group, it is characterized in that four kinds of blended optimum ratios of blood group blood plasma are: 5 parts of A type blood plasma, 2 parts of Type B blood plasma, 2 parts of O type blood plasma, 1 part of AB type blood plasma.
7, by claim 1 or 2 described freeze-dried plasma without blood group, it is characterized in that four kinds of blended optimum ratios of blood group blood plasma are: 5 parts of A type blood plasma, 3 parts of Type B blood plasma, O type blood plasma 1,1 part of AB type blood plasma.
8, by claim 1 or 2 described freeze-dried plasma without blood group, it is characterized in that four kinds of blended optimum ratios of blood group blood plasma are: 5 parts of A type blood plasma, 3.5 parts of Type B blood plasma, O type blood plasma 0.5,1 part of AB type blood plasma.
9, by claim 1 or 2 described freeze-dried plasma without blood group, it is characterized in that four kinds of blended optimum ratios of blood group blood plasma are: 6 parts of A type blood plasma, 3 parts of Type B blood plasma, O type blood plasma 0.5,0.5 part of AB type blood plasma.
10, a kind of preparation method of freeze-dried plasma without blood group; it is characterized in that the qualified blood plasma speed of gathering is put-30 ℃ of stored frozen, proportioning is mixed four kinds of molten slurries of blood group blood plasma by measure, adds an amount of protective agent; carry out viral inactivation treatment with the S/D method; ultrafiltration and concentration adds protective agent again, adjusts pH value 7.4 ± 1.0; the degerming packing; revolve under≤-30 ℃ temperature at last and freeze, lyophilizing is handled under≤35 ℃ temperature and in≤50 hour time again, makes the frozen dry blood plasma preparation.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011066377A CN1207004C (en) | 2001-04-18 | 2001-04-18 | Freeze-dried plasma without blood group and its preparation method |
| PCT/CN2002/000264 WO2002083157A1 (en) | 2001-04-18 | 2002-04-17 | Blood group-free human blood plasma and the preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011066377A CN1207004C (en) | 2001-04-18 | 2001-04-18 | Freeze-dried plasma without blood group and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1321468A true CN1321468A (en) | 2001-11-14 |
| CN1207004C CN1207004C (en) | 2005-06-22 |
Family
ID=4655626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB011066377A Expired - Lifetime CN1207004C (en) | 2001-04-18 | 2001-04-18 | Freeze-dried plasma without blood group and its preparation method |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN1207004C (en) |
| WO (1) | WO2002083157A1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005058334A1 (en) * | 2003-12-19 | 2005-06-30 | Octapharma Ag | A universally applicable virus inactivated blood plasma produced from portions of non-caucasian plasma |
| CN100431550C (en) * | 2005-01-12 | 2008-11-12 | 马建川 | Universal fresh frozen blood plasma |
| JP2013534241A (en) * | 2010-08-16 | 2013-09-02 | エタ・フランセ・（ミニステル・ドゥ・ラ・デファンス）・セルヴィス・ドゥ・サンテ・デ・アルメ | Plasma freeze-drying method |
| CN105832768A (en) * | 2015-08-11 | 2016-08-10 | 杜祖英 | Human plasma with multiple functions and preparation method thereof |
| CN114617903A (en) * | 2022-03-15 | 2022-06-14 | 中国人民解放军总医院第一医学中心 | Composition for plasma freeze-drying and application thereof |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9561184B2 (en) | 2014-09-19 | 2017-02-07 | Velico Medical, Inc. | Methods and systems for multi-stage drying of plasma |
| JP7110360B2 (en) | 2017-10-09 | 2022-08-01 | テルモ ビーシーティー バイオテクノロジーズ，エルエルシー | Freeze-drying method |
| JP7471316B2 (en) | 2019-03-14 | 2024-04-19 | テルモ ビーシーティー バイオテクノロジーズ，エルエルシー | Multi-part freeze-drying container |
| US12083447B2 (en) | 2022-09-15 | 2024-09-10 | Velico Medical, Inc. | Alignment of a disposable for a spray drying plasma system |
| US11975274B2 (en) | 2022-09-15 | 2024-05-07 | Velico Medical, Inc. | Blood plasma product |
| US11998861B2 (en) | 2022-09-15 | 2024-06-04 | Velico Medical, Inc. | Usability of a disposable for a spray drying plasma system |
| US11841189B1 (en) | 2022-09-15 | 2023-12-12 | Velico Medical, Inc. | Disposable for a spray drying system |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4664913A (en) * | 1982-05-24 | 1987-05-12 | Xoma Corporation | Method for treating plasma for transfusion |
| CN1042474A (en) * | 1988-11-10 | 1990-05-30 | 济南军区药物研究中心 | Pectin plasma substitute and preparation method |
| EP0896824A1 (en) * | 1997-08-05 | 1999-02-17 | Octapharma Ag | A universally applicable blood plasma |
-
2001
- 2001-04-18 CN CNB011066377A patent/CN1207004C/en not_active Expired - Lifetime
-
2002
- 2002-04-17 WO PCT/CN2002/000264 patent/WO2002083157A1/en not_active Application Discontinuation
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005058334A1 (en) * | 2003-12-19 | 2005-06-30 | Octapharma Ag | A universally applicable virus inactivated blood plasma produced from portions of non-caucasian plasma |
| AU2004298790B2 (en) * | 2003-12-19 | 2010-04-08 | Octapharma Ag | A universally applicable virus inactivated blood plasma produced from portions of non-caucasian plasma |
| CN1893960B (en) * | 2003-12-19 | 2012-10-31 | 奥克塔法马股份有限公司 | A universally applicable virus inactivated blood plasma produced from portions of non-caucasian plasma |
| CN100431550C (en) * | 2005-01-12 | 2008-11-12 | 马建川 | Universal fresh frozen blood plasma |
| JP2013534241A (en) * | 2010-08-16 | 2013-09-02 | エタ・フランセ・（ミニステル・ドゥ・ラ・デファンス）・セルヴィス・ドゥ・サンテ・デ・アルメ | Plasma freeze-drying method |
| CN105832768A (en) * | 2015-08-11 | 2016-08-10 | 杜祖英 | Human plasma with multiple functions and preparation method thereof |
| CN114617903A (en) * | 2022-03-15 | 2022-06-14 | 中国人民解放军总医院第一医学中心 | Composition for plasma freeze-drying and application thereof |
| CN114617903B (en) * | 2022-03-15 | 2024-05-24 | 中国人民解放军总医院第一医学中心 | Composition for freeze-drying blood plasma and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1207004C (en) | 2005-06-22 |
| WO2002083157A1 (en) | 2002-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1207004C (en) | Freeze-dried plasma without blood group and its preparation method | |
| Conley et al. | X-linked agammaglobulinemia | |
| US4027013A (en) | Clottable fibrinogen free factor VIII and albumin product and process | |
| FR2963737A1 (en) | PROCESS FOR THE LYOPHILIZATION OF BLOOD PLASMA | |
| Marsh et al. | Separation and partial characterization of a coagulant enzyme from Bitis gabonica venom | |
| Green et al. | Use of factor-VII-rich prothrombin complex concentrate in liver disease | |
| US20110104298A1 (en) | Universally applicable virus inactivated blood plasma produced from portions of non-Caucasians plasma | |
| CN1215850C (en) | Fresh refrigerated plasma without blood group | |
| CN102430116A (en) | Dry heat treatment method for human coagulation factor VIII preparation and dry heat treatment stabilizer | |
| Pollard | The chemical composition of the active agent of the Rous sarcoma No. 1 and of some related products | |
| CN105832768A (en) | Human plasma with multiple functions and preparation method thereof | |
| CN1548534B (en) | Reptilase and its production process and application | |
| Haanen et al. | Preparation and clinical use of factor IX concentrate PPSB according to Soulier | |
| CN100368017C (en) | Compound bioogic component and pharmaceutical preparation possessing function for accelerating hemoglutination | |
| Rosenthal | The therapy of disorders of coagulation | |
| CN1162160C (en) | Low-condensing agent universal freeze-dried blood plasma | |
| CN106520736B (en) | A method of saving white-browed snake venom blood coagulation enzyme concentrate | |
| Spillert et al. | Protective effect of a splenic extract in mice with endotoxemia | |
| CN117462574A (en) | Product for improving immunity | |
| CN1168455C (en) | Low agglutinin universal refrigerated plasma | |
| CN116814601A (en) | Bacillus subtilis plasmin freeze-dried powder and preparation method and application thereof | |
| CN1083361A (en) | Antibacterial antiviral oral liquid | |
| CN112316148A (en) | Use of a semi-fluid comprising plasma, pharmaceutical compositions comprising the semi-fluid and an active ingredient and process for preparing the same | |
| JPH0567159B2 (en) | ||
| Cook | Antitetanus Immunization |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PD01 | Discharge of preservation of patent |
Date of registration: 20061220 Pledge (preservation): Preservation |
|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Ma Jianchuan Document name: Notice of termination of proceedings |
|
| C56 | Change in the name or address of the patentee |
Owner name: SHANDONG MICHELLE BIOLOGICAL ENGINEERING CO., LTD. Free format text: FORMER NAME OR ADDRESS: MA JIANCHUAN |
|
| CP03 | Change of name, title or address |
Address after: Room 3, building 52, No. 206, East Jiaotong University Road, Beijing, Haidian District Patentee after: Shandong Michel Biological Engineering Co., Ltd. Address before: Shuming road Chengdu City, Sichuan Province Road No. 3 happy Shu Feng Jing A-2-11B Patentee before: Ma Jianchuan |
|
| ASS | Succession or assignment of patent right |
Owner name: WUHAN HUALONG TAIKANG BIOLOGICAL PRODUCTS CO., LT Free format text: FORMER OWNER: SHANDONG MICHELLE BIOLOGICAL ENGINEERING CO., LTD. Effective date: 20081010 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20081010 Address after: 12, 3, 6, 1 floor, Hou Hu ecological garden, Jiang'an District, Wuhan, Hubei Patentee after: Wuhan Hualong Taikang biologicals Co., Ltd. Address before: Room 3, building 52, No. 206, East Jiaotong University Road, Beijing, Haidian District Patentee before: Shandong Michel Biological Engineering Co., Ltd. |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050622 Termination date: 20120418 |
|
| RR01 | Reinstatement of patent right |
Former decision: termination of patent right due to unpaid annual fee Former decision publication date: 20131204 |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20050622 |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Patent of Wuhan Hualong Taikang Biological Products Co.,Ltd. The person in charge Document name: Notice of termination of patent right |